Primaquine-tolerant vivax malaria in Thailand
Primaquine-tolerant vivax malaria in Thailand
复制标题
DOI：
10.1080/00034989760338
复制
发表时间：
1997-12-01
影响因子：
--
通讯作者：
Walsh, DS
中科院分区：
文献类型：
--
作者：
Looareesuwan, S;Buchachart, K;Walsh, DS
间日疟原虫感染引起显著的发病率。除了原发性感染，休眠的肝脏阶段可能在治疗后很长时间内重新出现，导致复发。伯氨喹是唯一可用于间日疟原虫（和卵形疟原虫）感染“根治”（即根除肝催眠虫以防止复发）的药物，已成功使用数十年（柯林斯和Jeffery，1996）。然而，一些间日疟原虫株，特别是来自西太平洋和东南亚的间日疟原虫株，对伯氨喹的敏感性表现出变异性
Plasmodium vivax infections cause significant morbidity. In addition to the primary infection, dormant liver stages may reemerge, long after treatment, to cause relapse. Primaquine, the only drug available for the'radical cure'(ie eradication of the hepatic hypnozoites to prevent relapse) of P. vivax (and P. ovale) infections, has been used successfully for many decades (Collins and Jeffery, 1996). However, some vivax strains, particularly those from the western Pacific and South-east Asia, exhibit variability in their sensitivity to primaquine